Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunityJean-René Pallandre, Emilie Brillard, Gilles Créhange, et al.
ACS Nano|November 19, 2025
A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving RadioenhancementSebastian Jung, Pedro Lopez Navarro, Elsa Barbé, et al.
Anti-Cancer Drugs|September 22, 2010
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumorsAntoine Thiery-Vuillemin, Erion Dobi, Thierry Nguyen, et al.
Cancer Causes & Control : CCC|December 19, 2007
Cancer screening in France: subjects' and physicians' attitudesFrançois Eisinger, Jean-Yves Blay, Jean-François Morère, et al.
Cancer Research and Treatment|December 29, 2017
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast CancerRenaud Sabatier, Véronique Diéras, Xavier Pivot, et al.
BMC Cancer|April 17, 2008
Impact of organised programs on colorectal cancer screeningFrançois Eisinger, Laurent Cals, Anne Calazel-Benque, et al.
Bulletin Du Cancer|October 9, 2014
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]Jean-Yves Pierga, Rémy Delva, Xavier Pivot, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOXavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
Breast (Edinburgh, Scotland)|April 29, 2022
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER studyJoseph Gligorov, Xavier Pivot, Beyhan Ataseven, et al.
The Lancet. Oncology|August 23, 2013
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyXavier Pivot, Joseph Gligorov, Volkmar Müller, et al.
Pageof 21